ModifiedPremera BluecrossPolicy 5.01.33

Pharmacologic Treatment of Postpartum Depression

Criteria for medical necessity of Zurzuvae (zuranolone) for treatment of postpartum depression in adults, plus documentation, administration, and background/evidence relevant to coverage decisions.

Policy Summary

PayerPremera Bluecross

PolicyPharmacologic Treatment of Postpartum Depression

Policy CodePolicy 5.01.33

Change TypeRemoved brexanolone coverageclarified exception durationupdated age guidance

Effective DateMay 1, 2026

Next Review DateMay 1, 2026

Key ActionObtain prior authorization through the pharmacy benefit and document DSM-5 diagnosis and moderate-to-severe severity to support coverage.

SourceLink

POLICY UPDATE CHANGES

Removed coverage criteria for Zulresso (brexanolone) as product has been removed from the market.

Non-formulary exception review authorizations for all drugs listed in this policy may be approved up to 12 months.

Age criterion updated from 18 years or older to 15 years or older for treatment with Zulresso (previously) based on available pharmacokinetic and safety data.

14max course per pregnancy (days)

15minimum age (years)

≤12postpartum window (months)

50recommended dose (mg)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

1drug removed from market

Coverage Criteria for Zurzuvae (zuranolone)

Medical necessity criteria for Zurzuvae (zuranolone)

Covered when ALL of the following are met:

Adult age: Individual is aged 18 years or olderage >=18

DSM-5 diagnosis: Medical record documents DSM-5 diagnostic criteria for Major Depressive Disorder with peripartum onsetperipartum onset

Severity: Current episode is moderate to severe as demonstrated by documentation of individual's symptoms and their severity or by one or more standardized depression rating scalese.g., HAMD >=18 or PHQ-9 >=10

Severity thresholds provided in policy

Postpartum timing: Individual is 12 months or less postpartum<=12 months postpartum

Treatment course limit: Treatment course is limited to 14 days14 days per pregnancy

Re-authorization beyond 14 days in a single treatment course per pregnancy is considered not medically necessary

Pharmacologic therapy coverage criteria

Covered when ALL of the following are met

Age and diagnosis: Individual meets age eligibility (policy updated to allow 15 years and older where supported) and has a diagnosis of postpartum depressionage >= 15 years

Age change documented in 2022 update

Severity documentation: Documentation demonstrates moderate to severe depression via symptoms or standardized rating scale(s)e.g., elevated PHQ-9 score or equivalent

Policy guidance added to define moderate to severe depression

Prior authorization and formulary exception: Prior authorization obtained for the drug; non-formulary exception reviews may be approved up to 12 monthsauthorization in place

All uses of Zurzuvae (zuranolone) that are not expressly described in this policy are considered not medically necessary. Coverage is limited to the specific indications and criteria listed for treatment of postpartum depression; requests for other diagnoses or uses will be denied.

Zulresso (brexanolone) has been removed from the policy because the product was removed from the market. As a result, coverage criteria referencing brexanolone have been deleted and prior-authorizations or requests for Zulresso will not be approved.

Treatment with Zurzuvae (zuranolone) is limited to a single course of 14 days per pregnancy. Any request to re-authorize or extend a treatment course beyond 14 days for the same pregnancy is considered not medically necessary and will be denied.

There is no national Medicare coverage determination (NCD) specific to zuranolone; in the absence of an NCD, local Medicare contractors determine coverage for Medicare beneficiaries. Providers should consult applicable local Medicare carrier policies when managing coverage for Medicare members.

Coding and Severity Thresholds

Previously listed HCPCS codes (removed)HCPCSNot Covered

J1632

Brexanolone injection (previously listed)

Depression severity thresholds — standardized scales

HAM-D (Hamilton Depression Rating Scale)Score ≥18 = moderate to severe depression

PHQ-9 (Patient Health Questionnaire-9)Score ≥10 suggests likely major depression (10–14 = moderate; 15–19 = moderately severe; ≥20 = severe)

MADRS (Montgomery-Åsberg Depression Rating Scale)Score 20–34 = moderate; ≥35 = severe

QIDS-SR (Quick Inventory of Depressive Symptomatology - Self Report)Score 11–15 = moderate; 16–20 = severe; ≥21 = very severe

Minimum age for therapy (policy history)

Minimum age for therapy (policy update)Policy updated in 2022 to allow consideration of treatment in individuals aged 15 years and older where supported by data

Prior Authorization, Documentation, and Provider Actions

Prior Authorization

Pharmacy benefit prior authorization

Zurzuvae (zuranolone) is managed through the pharmacy benefit and requires prior authorization when criteria apply.

Zurzuvae (zuranolone) — pharmacy benefit; prior authorization required when medical necessity criteria apply.

Documentation Required

Required medical record documentation

The individual’s medical records submitted for review must document that medical necessity criteria are met. Medical record documentation should include office visit notes with relevant history and physical evaluation information and documentation of DSM-5 diagnostic criteria and depression severity.

Include office visit notes with relevant history and physical exam.
Document DSM-5 diagnostic criteria for Major Depressive Disorder with peripartum onset.
Document current episode is moderate to severe by symptoms or a standardized rating scale (e.g., HAM-D, MADRS, QIDS-SR, PHQ-9).

Definitions and Rating Scales

Major Depressive Episode (DSM-5) — diagnostic criteria summary

Core symptom requirementFive (or more) specified symptoms present during the same 2‑week period representing a change from prior functioning; at least one must be depressed mood or loss of interest/pleasure

Symptom examplesDepressed mood; markedly diminished interest/pleasure; significant weight/appetite change; insomnia or hypersomnia; psychomotor agitation/retardation; fatigue; worthlessness/guilt; impaired concentration; recurrent thoughts of death or suicidal ideation

Functional impact and exclusionsSymptoms cause clinically significant distress/impairment and are not attributable to substances or another medical condition; absence of prior manic/hypomanic episode applies

Depression severity scales — severity cutoffs

HAM-D<10 remission; 10–13 mild; 14–17 mild to moderate; ≥18 moderate to severe

Level of Care

Outpatient — level of care criteria

Screening positive: Pregnant or postpartum persons who screen positive for depression or are at increased risk per USPSTF should be referred to counseling interventions or evaluated for treatmentper USPSTF

Screening recommendation is USPSTF category B

Clinical response: Continued pharmacologic treatment requires documentation of benefit or ongoing need; use standardized measures to document response and severitydocumented improvement or clinical justification

Policy references standardized rating scales such as PHQ-9

Permitted Treatment Modalities

Medication (Zurzuvae / zuranolone)

Dose and administration: Recommended dose is 50 mg orally once daily in the evening for 14 days; dose may be reduced to 40 mg if CNS depressant effects occur; 30 mg recommended for strong CYP3A4 inhibitors or severe hepatic impairment (Child-Pugh C) or severe renal impairment (eGFR <60 mL/min/1.73 m2)50 mg QD x14 days; adjust to 40 mg or 30 mg per conditions

Safety warnings: Zuranolone has a boxed warning regarding driving impairment due to CNS depressant effects; individuals advised not to drive until at least 12 hours after administrationno driving for >=12 hours after dose

Serious adverse events 1.0-2.8% in trials; common AEs include somnolence, dizziness, sedation, headache

Psychotherapy / Nonmedication therapy

Background and Evidence

Postpartum depression affects an estimated 10–20% of women after childbirth, with a substantial proportion of cases classified as moderate to severe. The precise pathogenesis is not fully established but is thought to involve hormonal fluctuations after delivery and alterations in central nervous system signaling, including GABAergic pathways and hypothalamic–pituitary–adrenal axis changes. Zuranolone is a neuroactive steroid that modulates GABA-A receptors and is indicated for postpartum depression; policy criteria require documentation of a DSM-5 diagnosis of Major Depressive Disorder with peripartum onset and evidence of moderate to severe current episode using symptoms or standardized rating scales.

Revision History and Policy Changes

2026-05-01policy_updateLatest

Removed coverage criteria for Zulresso (brexanolone) and removed associated HCPCS code J1632 after the product was removed from the market.

2025clarification

Clarified that non‑formulary exception review authorizations for drugs listed in this policy may be approved for up to 12 months and confirmed medications are subject to FDA dosing and administration guidance.

2022-10-01eligibility_revision

Policy Summary

PayerPremera Bluecross

PolicyPharmacologic Treatment of Postpartum Depression

Policy CodePolicy 5.01.33

Change TypeRemoved brexanolone coverageclarified exception durationupdated age guidance

Effective DateMay 1, 2026

Next Review DateMay 1, 2026

Key ActionObtain prior authorization through the pharmacy benefit and document DSM-5 diagnosis and moderate-to-severe severity to support coverage.

SourceLink

On This Page

Clarified in 2025 update

Default adult age in primary Zurzuvae criteriaPrimary medical necessity criteria specify age 18 years or older for Zurzuvae coverage

RationaleAge change to 15–17 supported by pharmacokinetic and safety data referenced in the 2022 update

Document postpartum timing (within 12 months) and patient age criteria.

Documentation Required

Psychotherapy consideration

Psychotherapy or other nonmedication therapies may be considered first for some women and should be part of the treatment plan whenever appropriate. Antidepressant therapy is often prescribed per standard MDD pathways; document consideration of psychotherapy and rationale when initiating pharmacologic treatment.

Document that psychotherapy or nonmedication therapies were considered and whether they were attempted or are part of the treatment plan.
If initiating pharmacotherapy, document the rationale for choosing medication over or in addition to psychotherapy.

Prior Authorization

Drug prior authorization and formulary exception

Non-formulary exception review authorizations for drugs listed in this policy may be approved for up to 12 months. Requests referencing brexanolone (Zulresso) may be denied as the product has been removed from the market.

Non-formulary exception approvals: up to 12 months.
Brexanolone (Zulresso): denial risk — product removed from market.

0–6 none; 7–19 mild; 20–34 moderate; ≥35 severe

QIDS-SR0–5 none; 6–10 mild; 11–15 moderate; 16–20 severe; ≥21 very severe

PHQ-90–4 none; 5–9 mild; 10–14 moderate; 15–19 moderately severe; ≥20 severe (PHQ‑9 ≥10 indicates likely major depression)

Postpartum period — definition

Definition of postpartum periodPersons who are less than 1 year (≤12 months) postpartum are included for screening and treatment considerations

USPSTF relevanceUSPSTF recommendations apply to pregnant persons and those <1 year postpartum for screening and counseling (category B)

Clinical implicationPostpartum timing (≤12 months) is an eligibility threshold for policy coverage of Zurzuvae

Moderate to severe depression — acceptable documentation

Documentation to demonstrate moderate to severe depressionMedical record may document symptoms and severity consistent with DSM‑5 criteria or use one or more standardized depression rating scales (e.g., PHQ‑9, HAMD) to show moderate to severe range

Alternative documentationClinician notes describing symptom frequency, functional impairment, and clinical judgment may be used in lieu of a scale if clearly documented

Examples of acceptable scales and thresholdsPHQ‑9 ≥10, HAMD ≥18, MADRS ≥20 (moderate) or QIDS‑SR ≥11 (moderate)

Nonpharmacologic options: Depression-focused psychotherapy or other nonmedication therapies may be considered first for some women; interpersonal therapy is best studiednone

Psychotherapy should be considered as part of the treatment plan whenever possible

ECT

ECT: Electroconvulsive therapy is recommended as a treatment option for major depressive disorder during pregnancy when indicatedclinical indication for ECT

APA guideline excerpt

Pharmacologic (neuroactive steroids)

Neuroactive steroids: Zuranolone is listed in the policy as a pharmacologic option for postpartum depression; prescribing should follow FDA product labelingfollow FDA dosing and administration

Prescribing information reviewed; see references

Lowered the age eligibility in the policy from 18 years to 15 years where supported by pharmacokinetic and safety data.